Trisalus Life Sciences, Inc. · NASDAQ:TLSI
Trisalus Life Sciences — Investor Presentation (August 2025)
25 slides from Trisalus Life Sciences's investor presentation, August 2025
Slide 1: Investor Presentation
Investor Presentation August 2025 1
Slide 2: Disclaimer
Disclaimer This presentation contains “forward-looking statements” pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. The words “anticipate,” “conti
Slide 3: TriSalus at a Glance
TriSalus at a Glance • Pressure Enabled Drug Delivery (PEDD ) infusion improves delivery of therapeutics to HCC, Improving Drug Delivery for pancreatic cancer, and other solid tumors to Solid Tumors • Nelitolimod, a TLR9 agonist, delivered via PEDD to liver and pancreatic tumors High Growth, Commerc
Slide 4: Tumor Microenvironment Limits Drug in Solid Tumors
Tumor Microenvironment Limits Drug in Solid Tumors High intra-tumoral pressure in solid tumors limits efficient drug delivery to tumor Limited drug uptake due to collapsed vessel Elevated interstitial fluid pressures reduce movement of fluid from vessel into tissue Lymphatic system within tumors is
Slide 5: PEDD Opens Collapsed Vessels for Improved Drug Delivery
PEDD Opens Collapsed Vessels for Improved Drug Delivery Angiogram of liver tumor vessels demonstrating Surefire Surefire Surefire increases Surefire TM pressure increases Standard PEDD during pressure Catheter Standard methodCatheter in Highinfusion, duringPressureovercom infusion, ingPEDD overcom P
Slide 6: Increased Drug Delivery to Tumor Correlates with Improved Survival Rates (OS)
Increased Drug Delivery to Tumor Correlates with Improved Survival Rates (OS) 6
Slide 7: Platform: Pressure Enabled Drug Delivery for Improved Drug Delivery
Platform: Pressure Enabled Drug Delivery for Improved Drug Delivery 510(k) product portfolio for vascular access throughout TriNav® Infusion System the body except the heart and brain TriNav Validated in multiple clinical and HEOR studies TriNav LV TriNav FLX Unique HCPCS reimbursement codes (both m
Slide 8: Improved Health and Economic Outcomes
Improved Health and Economic Outcomes Real-World Data Analysis Supports TriNav® Treatment in Complex Liver Cancer Patients1 POPULATION/SETTING COMPARATIVE FINDINGS Retrospective analysis of 300 million patient In chemoembolizations, TriNav® delivered 40% more doxorubicin claims over 3 years Higher d
Slide 9: TriSalus Specific Procedural Reimbursement for PEDD
TriSalus Specific Procedural Reimbursement for PEDD Procedure code secures long-term access for TriSalus technology PEDD Specific PEDD Specific Private Payer 01 Simulation Code 02 Treatment Code 03 Patients CMS issued New CMS HCPCS Code CMS issued HCPCS procedural code Commercial payers generally fo
Slide 10: Focused Call Point Fuels Standard of Care Momentum for Locoregional Delivery
Focused Call Point Fuels Standard of Care Momentum for Locoregional Delivery Growth Drivers Targeting ~400 hospitals vast majority of procedure volume Clinical Evidence HEOR Data Expanded Mapping Reimbursement Targeting ~450 of 1,000 Interventional Radiologists who perform embolizations Launch of Tr
Slide 11: Interventional Radiologist: Central Access Point for Full Value of Platform Portfolio
Interventional Radiologist: Central Access Point for Full Value of Platform Portfolio Liver Tumors (~62K patients) Multinodular Goiter (~50K patients) Uterine Fibroid Embolization (~20K Patients) Genicular Artery Embolization (~100K Patients) Prostate Embolization (~25K Patients) Single, Accessible
Slide 12: Combined U.S. PEDD TAM Estimated ~$2.5B Annually
Combined U.S. PEDD TAM Estimated ~$2.5B Annually Efficient expansion opportunity with minimal spend on R&D, Salesforce Indication(s) # Patients Market/timing Liver (HCC + Colorectal Liver Mets + Neuro 62,0001,2,3 Current Endocrine) Multinodular Goiter 50,0002 Adjacent Applications Uterine Fibroid Em
Slide 13: Addressable Markets
Addressable Markets AgTriSalus
Slide 14: Multinodular Goiter - ~$400 million U.S. Market Opportunity
Multinodular Goiter - ~$400 million U.S. Market Opportunity High unmet need for minimally invasive treatment option for Multinodular Goiter ~5% of population affected Current Standard of Care Risk factors Watchful waiting Iodine deficiency Medical therapy Female sex Surgery (Thyroidectomy) Metabolic
Slide 15: Uterine Fibroid Care - ~$115 million U.S. Market Opportunity
Uterine Fibroid Care - ~$115 million U.S. Market Opportunity U.S. Market characterized by high unmet need with continued expected growth1,2 ~10% of population affected Current Standard of Care Current Standard of Care Current UFE procedures often result in severe Women 18-65 live with Hysterectomy p
Slide 16: Locally Advanced Pancreatic Cancer - ~$400 Million U.S. Market Opportunity
Locally Advanced Pancreatic Cancer - ~$400 Million U.S. Market Opportunity High unmet need for Significant Unmet Clinical Need Current Standard of Care improved treatments Locally Advanced Adenocarcinoma ~30-50% Multi-agent chemotherapy patients ineligible primary treatment for for surgery most pati
Slide 17: Novel PEDD Method for the Pancreas, currently being assessed in Phase 1 studies
TriSalus Developed a Separate, Novel PEDD Method for the Pancreas, currently being assessed in Phase 1 studies • Poor blood flow limits drug access to pancreas1,2,3 • Pancreatic arteries difficult to access4,5 • Innovative retrograde venous approach eliminates need for balloons that eliminate blood
Slide 18: Unique Technology for Pancreatic Tumors Demonstrates Potential of PEDD Platform
Unique Technology for Pancreatic Tumors Demonstrates Potential of PEDD Platform Key ongoing studies Significant additional upside PERIO-3 Ph1 trial at MDACC administering nelitolimod via PEDD Early data indicate successful immunomodulation On-track for data read-out Q3 2025 Y90 Study with Boston Sci
Slide 19: Genicular Artery Embolization - ~$800 million U.S. Market Opportunity
Genicular Artery Embolization - ~$800 million U.S. Market Opportunity U.S. Market1 Population Affected Current Standard of Care Opportunity ~Market anticipated to grow to ~167,000 by 2030 Total knee arthroplasty (TKA) is 37 % Patients over 60 the SOC for individuals with Significant opportunity to r
Slide 20: Corporate
Corporate ATriSalus’
Slide 21: Multi-Layered Patents and Exclusivity Provides Long Term Protection
Multi-Layered Patents and Exclusivity Provides Long Term Protection Overview of Parent Multi-Layered Protection and PEDD Portfolio Market Exclusivity between 2030-2040 PEDD Devices 79 Registered Patents* PEDD Platform IP PEDD Device & Drug Class IP 95 Methods of Treatment (MoT): Pending patent appli
Slide 22: TriSalus at a Glance
TriSalus at a Glance Nasdaq TLSI Shares Outstanding:* ~49.9 million common shares outstanding Q2 2025 Ending Cash Balance: $26.5 Million Runway: Adjusted EBITDA Positivity Early to Mid 2026 Financial Highlights Q2 2025 Revenue: $11.2 million (+22% quarter-over-quarter) Q2 Adjusted EBITDA: ($5.3 mill
Slide 23: Veteran Industry Leadership
Veteran Industry Leadership Jodi Devlin Mary Szela David Patience Richard Marshak, VMD Jennifer Stevens Bryan Cox, PHD Richard Marshall, MD Chief of Clinical CEO & President Chief Financial Officer Chief Commercial Officer Chief Regulatory Officer Chief of Research Medical Director Strategy & Operat
Slide 24: Near-term milestones
Near-term milestones APPLICATION 1H25 H2 2025 H1 2026 H2 2026 TriNav® FLX Launch TriNav® Advance Launch TACE: Bi-Lobar ORR Study LIVER Anticipate PEDIR Anticipate Tri-FY90 publication publication TARE: T:N Ratio Imaging Study PROTECT Registry TAE PED-TAE Study: Journal of Endocrine Society TriNav® X
Slide 25: Thank You
Thank You trisaluslifesci.com 25
TriSalus Life Sciences — Investor Presentation (August 2025) on 6ix